|
|
Volumn 373, Issue 9670, 2009, Pages 1171-1172
|
|
Cytochrome P450 2C19 polymorphism and clopidogrel after MI
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CLOPIDOGREL;
CYTOCHROME P450 2C19;
ANTITHROMBOCYTIC AGENT;
CYP2C19 PROTEIN, HUMAN;
DRUG DERIVATIVE;
PRODRUG;
TICLOPIDINE;
UNSPECIFIC MONOOXYGENASE;
DNA POLYMORPHISM;
DRUG ABSORPTION;
DRUG MECHANISM;
GENETIC VARIABILITY;
GENOTYPE;
HEART INFARCTION;
HUMAN;
LETTER;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
PROGNOSIS;
STROKE;
GENETIC POLYMORPHISM;
GENETICS;
HETEROZYGOTE;
METABOLISM;
METHODOLOGY;
MORTALITY;
NOTE;
TREATMENT OUTCOME;
FOLLOW UP;
PATIENT COMPLIANCE;
ARYL HYDROCARBON HYDROXYLASES;
GENOTYPE;
HETEROZYGOTE;
HUMANS;
MYOCARDIAL INFARCTION;
PLATELET AGGREGATION INHIBITORS;
POLYMORPHISM, GENETIC;
PRODRUGS;
PROGNOSIS;
RESEARCH DESIGN;
TICLOPIDINE;
TREATMENT OUTCOME;
FOLLOW-UP STUDIES;
MEDICATION ADHERENCE;
|
|
EID: 63349089626
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(09)60680-2 Document Type: Letter |
|
Times cited : (3)
|
|
References (5)
|
